Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- Area under the concentration versus time curve (AUC) of Tacrolimus and Mycophenolate mofetil
Study Overview
Brief Summary
Coadministration of tacrolimus and mycophenolate mofetil is frequent in kidney transplantation. Due to narrow therapeutic range of tacrolimus and mycophenolate mofetil, therapeutic drug monitoring with dose adjustment is required. Investigating pharmacokinetic interplay between two drugs enables fine dose adjustment, while mechanism of drug interaction between two drugs is still not well understood. Therefore, an open-label, three period, single dose trial is planned to investigate the drug interaction between tacrolimus and mycophenolate mofetil.
Detailed Description
Study consists of three periods with fixed sequence: 1) single dose of mycophenolate mofetil 1,000mg; 2) single dose of tacrolimus 5mg; 3) single dose of mycophenolate mofetil 1,000mg and tacrolimus 5mg. All subjects have one week of washing period between single dose administration. Blood samples are drawn up to 72 hours after drug administration. Single nucleotide polymorphisms known to result in pharmacokinetic variability of study drug are also investigated. Drug interaction is going to be assessed through the ratio of area under the concentration curve of one drug in the presence or absence of another drug.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 45 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male adult with age of 19-45
- •Weight difference between ideal and actual body weight is less than 20%
- •Previous healthy with no known disease
- •Considered normal on physical exam, clinical laboratory tests(complete blood count, electrolyte, renal and hepatic function) and electrocardiogram
- •Never been heavy-drinker within one month prior to trial initiation and able to abstain from alcohol during trial
Exclusion Criteria
- •Ever smoked within one year prior to trial initiation
- •Took other drugs (including herbal medicine) within one month prior to trial initiation
- •Alcohol or drug abuser
- •Participated another clinical trial within three months
- •Considered inadequate under investigator's discretion
Arms & Interventions
Tacrolimus and Mycophenolate mofetil
Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
Intervention: Mycophenolate mofetil (Drug)
Tacrolimus and Mycophenolate mofetil
Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
Intervention: Tacrolimus (Drug)
Outcomes
Primary Outcomes
Area under the concentration versus time curve (AUC) of Tacrolimus and Mycophenolate mofetil
Time Frame: 0, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose
Secondary Outcomes
- Adverse Drug Reaction(through study completion, an average of 1 month)
- Peak Concentration of Tacrolimus and Mycophenolate mofetil(0, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose)
Investigators
Yon Su Kim
Principal Investigator
Seoul National University Hospital